Novo Nordisk
NVO
#31
Rank
$262.07 B
Marketcap
$103.20
Share price
-1.22%
Change (1 day)
3.74%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Revenue for Novo Nordisk (NVO)

Revenue in 2022 (TTM): $53.85 B

According to Novo Nordisk's latest financial reports the company's current revenue (TTM) is $53.85 B. In 2021 the company made a revenue of $52.36 B an increase over the years 2020 revenue that were of $48.02 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novo Nordisk from 2001 to 2022

Annual revenue

Year Revenue Change
2022 (TTM)$53.85 B2.84%
2021$52.36 B9.03%
2020$48.02 B18.51%
2019$40.52 B13.1%
2018$35.83 B5.17%
2017$34.07 B17.83%
2016$28.91 B7.23%
2015$26.96 B19.61%
2014$22.54 B7.97%
2013$20.87 B14.57%
2012$18.22 B48.7%
2011$12.25 B14.14%
2010$10.73 B11.21%
2009$9.65 B6.07%
2008$9.10 B15.82%
2007$7.85 B18.71%
2006$6.62 B20.12%
2005$5.51 B12.16%
2004$4.91 B13.53%
2003$4.32 B10.2%
2002$3.92 B0.74%
2001$3.89 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
$101.13 B 87.80%๐Ÿ‡บ๐Ÿ‡ธ USA
$29.32 B-45.55%๐Ÿ‡บ๐Ÿ‡ธ USA
$44.78 B-16.83%๐Ÿ‡ซ๐Ÿ‡ท France
$46.44 B-13.75%๐Ÿ‡บ๐Ÿ‡ธ USA